Alnylam Pharmaceuticals (ALNY) PT Raised to $107 at Stifel

JPMorgan Upgrades Alnylam Pharmaceuticals (ALNY) to Overweight

JPMorgan upgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Neutral to Overweight with a price target of $162.00 (from $86.00).

Analyst Anupam Rama believes givosiran remains underappreciated on the Street and as a driver of upside for the company. The analyst also is expecting a smooth... More

Alnylam Pharmaceuticals (ALNY) PT Raised to $158 at Barclays on 3Q Report; 'Multiple Programs Progressing to Approval/Late-Stage Development'

Barclays raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $158.00 (from $127.00) while maintaining a Overweight rating, following the company's third quarter earnings report.

Analyst Gena Wang notes a positive outlook on the shares, as the company reported third quarter earnings per share results above... More

Alnylam Pharma (ALNY) Tops Q3 EPS by 21c

Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.06), $0.21 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $17.1 million versus the consensus estimate of $24.65 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

Alnylam Pharma (ALNY) Initiates ENVISION Phase 3 Clinical Study with Givosiran to Treat AHPs

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the initiation of the ENVISION Phase 3 clinical study with givosiran, a subcutaneously administered, investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias (AHPs). The Company is also reiterating... More

Medicines Co. (MDCO), Alnylam Pharmaceuticals (ALNY) Announce Initiation of Phase III Clinical Trials of Inclisiran

The Medicines Company (NASDAQ: MDCO) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the initiation of the Phase III clinical program for inclisiran, with the commencement of patient dosing on November 1, 2017 in the ORION-11 trial, a Phase III study of inclisiran versus placebo in patients with atherosclerotic cardiovascular disease (ASCVD), or ASCVD-risk equivalents (e.g., type 2 diabetes and familial hypercholesterolemia), and elevated LDL-cholesterol (LDL-C) despite maximum tolerated doses of LDL-C lowering therapies.

The ORION-11 trial is a double-blind study in which 1,500 eligible patients will... More